08:38 AM EDT, 10/17/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Friday that its investigational drug Verzenio, combined with endocrine therapy, reduced the risk of death by 15.8% compared to endocrine therapy alone in patients with a certain type of breast cancer.

Results from a phase 3 trial showed a seven-year overall survival rate of 86.8% for Verzenio plus endocrine therapy compared to 85% for endocrine therapy alone, the company said.

Verzenio also showed long-term improvements in invasive disease-free survival and distant relapse-free survival, Eli Lilly ( LLY ) said

Eli Lilly ( LLY ) said the safety profile was consistent with earlier data, and no new safety signals were observed.

Shares of Eli Lilly ( LLY ) were down 3.8% in recent Friday premarket activity.